[go: up one dir, main page]

LT3359185T - Priešnavikinė kompozicija - Google Patents

Priešnavikinė kompozicija

Info

Publication number
LT3359185T
LT3359185T LTEPPCT/FR2016/052598T LT16052598T LT3359185T LT 3359185 T LT3359185 T LT 3359185T LT 16052598 T LT16052598 T LT 16052598T LT 3359185 T LT3359185 T LT 3359185T
Authority
LT
Lithuania
Prior art keywords
cumor
composition
cumor composition
Prior art date
Application number
LTEPPCT/FR2016/052598T
Other languages
English (en)
Inventor
Jean-Marc Limacher
Original Assignee
Jean-Marc Limacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jean-Marc Limacher filed Critical Jean-Marc Limacher
Publication of LT3359185T publication Critical patent/LT3359185T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEPPCT/FR2016/052598T 2015-10-08 2016-10-07 Priešnavikinė kompozicija LT3359185T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1559589A FR3042121A1 (fr) 2015-10-08 2015-10-08 Composition anti-tumorale
FR1659450A FR3042122B1 (fr) 2015-10-08 2016-09-30 Composition anti-tumorale
PCT/FR2016/052598 WO2017060650A1 (fr) 2015-10-08 2016-10-07 Composition anti-tumorale

Publications (1)

Publication Number Publication Date
LT3359185T true LT3359185T (lt) 2022-06-27

Family

ID=55178130

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/FR2016/052598T LT3359185T (lt) 2015-10-08 2016-10-07 Priešnavikinė kompozicija

Country Status (14)

Country Link
US (2) US20180296653A1 (lt)
EP (1) EP3359185B1 (lt)
JP (1) JP7211815B2 (lt)
KR (1) KR20180059547A (lt)
CN (1) CN108348587A (lt)
CA (1) CA2999948C (lt)
DK (1) DK3359185T3 (lt)
ES (1) ES2919134T3 (lt)
FR (2) FR3042121A1 (lt)
HK (1) HK1253315A1 (lt)
IL (1) IL258430B (lt)
LT (1) LT3359185T (lt)
RU (1) RU2728748C2 (lt)
WO (1) WO2017060650A1 (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR20230030588A (ko) * 2020-06-30 2023-03-06 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
CN116676324B (zh) * 2023-07-28 2023-10-27 四川大学华西医院 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
WO1998013500A2 (en) 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
EP1021545A2 (en) 1997-09-23 2000-07-26 Bavarian Nordic Research Institute A/S Dengue virus antigens and treatment of dengue fever
CZ293690B6 (cs) 2000-03-14 2004-07-14 Bavarian Nordic A/S Modifikovaný virus vakcinie typu Ankara (MVA)
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
CN102409063A (zh) 2001-12-04 2012-04-11 巴法里安诺迪克有限公司 黄病毒ns1亚单位疫苗
BR0214822A (pt) 2001-12-10 2004-12-14 Bavarian Nordic As Formulações contendo poxvìrus e processo para preparar composições contendo poxvìrus estáveis
ES2247404T3 (es) 2001-12-20 2006-03-01 Bavarian Nordic A/S Metodo para la recuperacion y purificacion de poxvirus de celulas infectadas.
AU2003239805B2 (en) 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
NZ556144A (en) 2002-05-16 2008-04-30 Bavarian Nordic As Fusion protein comprising the amino acid sequence of at least three different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev and Tat, wherein the fusion protein does not contain specific clevage sequences for cellular proteases
DE60302848T2 (de) 2002-05-16 2006-08-31 Bavarian Nordic A/S Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
WO2003097845A1 (en) 2002-05-16 2003-11-27 Bavarian Nordic A/S Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
JP2006506991A (ja) 2002-11-25 2006-03-02 デン・コンゲリエ・ヴェテリネー−オ・ランボホイスコレ ブタ多型およびその検出のための方法
DE60314541T2 (de) 2002-11-25 2008-02-28 Bavarian Nordic A/S Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
WO2004092212A2 (en) * 2003-04-15 2004-10-28 Sanofi Pasteur Limited Tumor antigens bfa5 for prevention and/or treatment of cancer
ATE377088T1 (de) 2003-11-24 2007-11-15 Bavarian Nordic As Promotoren zur expression in modifiziertem vaccinia virus ankara
HUE030037T2 (en) 2005-02-23 2017-04-28 Bavarian Nordic As Use of modified anemic virus for rapid induction of immunity against gluten virus or other agents
EP2064351A1 (en) 2006-09-08 2009-06-03 Bavarian Nordic A/S Phenotypic and genotypic differences of mva strains
ES2500465T3 (es) 2006-10-06 2014-09-30 Bavarian Nordic Inc. Virus vaccinia Ankara modificado recombinante que codifica antígeno HER-2 en combinación con un taxano para uso en el tratamiento del cáncer
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
CA2676808C (en) 2007-04-27 2016-08-02 Bavarian Nordic A/S Induction of dendritic cell development with macrophage-colony stimulating factor (m-csf)
JP2010526546A (ja) 2007-05-14 2010-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製
EP2207564B1 (en) 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer
JP2011524159A (ja) 2008-05-26 2011-09-01 ティリアン・ダイアグノスティックス・リミテッド マイコバクテリウムによる感染の診断方法およびそのための試薬
EP2303322A1 (en) 2008-06-20 2011-04-06 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
KR101702956B1 (ko) 2008-11-21 2017-02-06 버베리안 노딕 에이/에스 다수의 상동성 뉴클레오티드 서열을 포함하는 벡터
AU2009319336B2 (en) 2008-11-27 2015-03-26 Bavarian Nordic A/S Promoters for recombinant viral expression
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US20120135032A1 (en) 2009-10-08 2012-05-31 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
DK2529010T3 (en) 2010-01-28 2017-07-24 Bavarian Nordic As MUTANTS OF VACCINIAVIRUS CONTAINING THE MAIN GENOMIC DELETIONS OF VAT
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
NZ608143A (en) 2010-10-15 2015-02-27 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) influenza vaccine
AU2011325459B2 (en) 2010-11-05 2016-11-10 Bavarian Nordic A/S Modulation of immune responses by the poxviral K4 protein
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
EA031453B1 (ru) 2012-08-01 2019-01-31 Бавариан Нордик А/С Рекомбинантный модифицированный вирус осповакцины анкара (mva) и его применение
US10973892B2 (en) 2012-09-04 2021-04-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
CA2888367A1 (en) 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
MY194609A (en) 2012-10-28 2022-12-06 Bavarian Nordic As Pr13.5 Promoter For Robust T-Cell And Antibody Responses
US9402888B2 (en) * 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
RU2714142C2 (ru) * 2013-11-05 2020-02-12 Бавариан Нордик А/С Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки
AU2014368898B2 (en) * 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
US10548930B2 (en) * 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors

Also Published As

Publication number Publication date
IL258430A (en) 2018-06-28
ES2919134T3 (es) 2022-07-22
FR3042122A1 (fr) 2017-04-14
HK1253315A1 (zh) 2019-06-14
US20210138053A1 (en) 2021-05-13
RU2018115534A3 (lt) 2020-02-26
US20180296653A1 (en) 2018-10-18
FR3042122B1 (fr) 2020-01-17
KR20180059547A (ko) 2018-06-04
CA2999948A1 (fr) 2017-04-13
FR3042121A1 (fr) 2017-04-14
CN108348587A (zh) 2018-07-31
RU2018115534A (ru) 2019-11-08
CA2999948C (fr) 2024-04-23
WO2017060650A1 (fr) 2017-04-13
JP2018531238A (ja) 2018-10-25
EP3359185A1 (fr) 2018-08-15
RU2728748C2 (ru) 2020-07-31
JP7211815B2 (ja) 2023-01-24
IL258430B (en) 2022-03-01
DK3359185T3 (da) 2022-07-04
EP3359185B1 (fr) 2022-04-06

Similar Documents

Publication Publication Date Title
EP3493800A4 (en) CANNABIS
DK3361870T3 (da) Fungicidsammensætninger
EP3339331A4 (en) COMPOSITION
EP3398996A4 (en) COMPOSITION
DK3416996T3 (da) Hærdelig sammensætning
DK3130649T3 (da) Haloolefin-baseret sammensætning
DK3542812T3 (da) Glycopeptidsammensætninger
FR3024363B1 (fr) Composition thermogelifiable
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3528902T3 (da) Ringegelsammensætning
EP3430073A4 (en) COMPOSITION BASED ON A POLYARYLETHERKETONE COMPOSITION
EP3395887C0 (en) FLUOROR RUBBER COMPOSITION
DK3322295T3 (da) Sammensætning
CL2017000639A1 (es) Composición
EP3480228A4 (en) COMPOSITION
DK3331498T3 (da) Nasalsammensætning
DK3316857T3 (da) Multifasiske sammensætninger
EP3556804A4 (en) COMPOSITION
DK3393254T3 (da) Sammensætning
LT3173071T (lt) Maropitanto kompozicija
EP3369418A4 (en) COMPOSITION
HUE070090T2 (hu) Összetétel
DE102015206660A8 (de) Plattenaufteilanlage
EP3443034C0 (en) COMPOSITION